Results 161 to 170 of about 29,384 (211)
Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam [PDF]
Antimicrobial Agents and Chemotherapy, 2017 Sulbactam is one of four β-lactamase inhibitors in current clinical use to counteract drug resistance caused by degradation of β-lactam antibiotics by these bacterial enzymes. As a β-lactam itself, sulbactam is susceptible to degradation by β-lactamases.
Adam Shapiro
exaly +2 more sources
Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study [PDF]
Expert Opinion on Drug Safety, 2020 Objectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding. Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with ...
Yu Wu, Jing Tan
exaly +2 more sources
The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms [PDF]
Journal of Microbiology, Immunology and Infection, 2018 Objectives: This study aims to assess the in vitro activity of cefoperazone alone and different cefoperazone-sulbactam ratios against different inoculum sizes of multidrug resistant organisms.
Yin-Ching Chuang +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Infection Control and Hospital Epidemiology, 1988
Sulbactam/ampicillin was recently marketed for use in several infections caused by beta-lactamase-producing organisms. Sulbactam is the second beta-lactamase inhibitor to become available in the United States. Interest in inhibition of beta-lactamases arose in the late 1960s when a combination consisting of an antibacterial agent and an enzyme ...
openaire +1 more source
Sulbactam/ampicillin was recently marketed for use in several infections caused by beta-lactamase-producing organisms. Sulbactam is the second beta-lactamase inhibitor to become available in the United States. Interest in inhibition of beta-lactamases arose in the late 1960s when a combination consisting of an antibacterial agent and an enzyme ...
openaire +1 more source